Registry for patients undergoing transcatheter mitral or tricuspid valve therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry collects data on patients treated with transcatheter mitral or tricuspid valve therapy at the Deutsches Herzzentrum München. It aims to assess long-term mortality outcomes following these interventions. The study includes all consecutive patients who meet the eligibility criteria and provides insights into the effectiveness of edge-to-edge valve repair techniques. Data will be gathered to enhance understanding of patient outcomes in this specific treatment context.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age above 18 years and consentable
* Mitral Valve Regurgitation, Mitral Valve Stenosis, Tricuspid Valve Regurgitation, Tricuspid Stenosis
* Transcatheter mitral or tricuspid valve therapy considered best option by heart-team decision
* Written informed consent

Exclusion Criteria:

* Patient's inability to fully cooperate with the protocol

Where it's running

• Deutsches Herzzentrum München des Freistaates Bayern, Technische Universität München
  Munich, Bavaria, Germany Recruiting

Study contacts

• Principal investigator: Tobias Rheude, MD — Dept. of Cardiology, Deutsches Herzzentrum München
• Study coordinator: Patrick Mayr, MD
• Email: mayrp@dhm.mhn.de
• Phone: +498912180

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tracking progression and consequences of heart valve disease

  This project will follow adults with moderate or worse valve disease to see if clinical tests and imaging can predict when their condition will get worse.

  Recruiting at 15 sites Second Affiliated Hospital, Zhejiang University, School of Medicine · Fuzhou, Fujian and 14 other locations · NCT07267117

• TruGamma tricuspid valve replacement for high-risk patients

  This trial tests the TruGamma tricuspid valve replacement system in high-risk patients with severe tricuspid regurgitation to see if it is safe and helps symptoms when added to standard medical care.

  Recruiting Jiangsu Trulive Medical Co., Ltd · Beijing, Beijing Municipality · NCT07691307

• Transcatheter Tricuspid Valve Replacement for Severe Tricuspid Regurgitation

  This trial tests the Laplace TTVR System to see if it safely and effectively treats adults with severe tricuspid regurgitation.

  Recruiting at 2 sites Laplace Interventional, Inc · Tulsa, Oklahoma and 1 other locations · NCT07687485

• How TAVI and M‑TEER affect sleep‑disordered breathing

  This will see if adults with aortic stenosis or mitral regurgitation who undergo TAVI or M‑TEER have improvements in sleep‑disordered breathing six months after their procedure.

  Recruiting Hippocration General Hospital · Athens, Attica · NCT07520656

• Vyne TriNova Transcatheter Tricuspid Valve Replacement study for severe tricuspid regurgitation

  This trial tests the VDyne TriNova system in adults with symptomatic severe tricuspid regurgitation to see if it is safe and helps heart symptoms compared with an alternative device.

  Recruiting at 12 sites VDyne, Inc. · Phoenix, Arizona and 11 other locations · NCT07516444

• Lead-related tricuspid valve leakage after first-time pacemaker or ICD implantation

  This project will see if a new transvenous pacemaker or ICD lead causes new or worse tricuspid valve regurgitation in people getting their first device.

  Recruiting Clinic for General and Interventional Cardiology/Angiology, Herz- und Diabeteszentrum NRW · Bad Oeynhausen, North Rhine-Westphalia · NCT07342036

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.